| Identification | Back Directory | [Name]
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide | [CAS]
708245-32-3 | [Synonyms]
2-methoxy-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide | [Molecular Formula]
C18H20N2O4S | [MOL File]
708245-32-3.mol | [Molecular Weight]
360.427 |
| Hazard Information | Back Directory | [Uses]
IRF1-IN-2 (Compound I-19) is an IRF1 inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4). IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury[1]. | [in vivo]
IRF1-IN-2 pretreatment (100?μg/d, s.c., one every other day before irradiation) has a potential protective effect in 35 Gy radiation-induced inflammatory skin injury mice[1].
| Animal Model: | Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)[1] | | Dosage: | 100 μg/d | | Administration: | Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment | | Result: | Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.
|
| [IC 50]
PARP-1; IL-1; Caspase-1 | [References]
[1] Geng, et al. Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response. Cell Mol Immunol. 2024 Aug;21(8):856-872. DOI:10.1038/s41423-024-01185-3 |
|
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|